Skip to content

Prevalence of Different Etiologies of Ocular Dryness in Patients Previously Diagnosed With Dry Eye Disease in A Sample of Egyptian Patients

Search Protocol 1. Study a-Proposed Study Title: Prevalence of Different Etiologies of Ocular Dryness in Patients Previously Diagnosed With Dry Eye Disease in A Sample of Egyptian Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05598437
Enrollment
200
Registered
2022-10-28
Start date
2022-11-01
Completion date
2023-04-30
Last updated
2022-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Syndromes, Dryness, Meibomian Gland Dysfunction

Keywords

Dry eye disease

Brief summary

Proposed Study Title: Prevalence of Different Etiologies of Ocular Dryness in Patients Previously Diagnosed with Dry Eye

Detailed description

Dry eye disease (DED) is a common chronic multifactorial condition of the ocular surface characterized by failure to produce high quality or sufficient amounts of tears to moisturize the eyes (1) DED can be categorized as dry eye with reduced tear production (aqueous deficient) and dry eye with increased evaporation of the tear film known as the hyperevaporative type… Although 10% of individuals have aqueous deficient DED, more than 80% have either the hyperevaporative type related to meibomian gland dysfunction (MGD), or a combination of

Interventions

DEVICEDry eye device

Dry eye analysis

Sponsors

Cairo University
CollaboratorOTHER
Roweis adel youssef
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Egyptian people between 20 and 70 years old coming to outpatient clinic BUT\< 10 seconds.. No previous surgery. No previous trauma. Not using eye drops in the last 3 months.

Exclusion criteria

Diabetic patients. Patients with rheumatological diseases that may affect ocular surface as RA.

Design outcomes

Primary

MeasureTime frameDescription
Meibomian gland dysfunction6 monthsMeibomian gland dysfunction

Countries

Egypt

Contacts

Primary ContactRoweis Adel
rowaisadel1992@gmail.com+21200797626
Backup ContactRoweis Adel
royceadel1992@gmail.com+21554558081

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026